Cargando…
The efficacy of tenofovir-based therapy in patients showing suboptimal response to entecavir-adefovir combination therapy
BACKGROUND/AIMS: Before tenofovir (TDF) become available in South Korea, combination therapy with entecavir (ETV) and adefovir (ADV) was the most potent regimen for chronic hepatitis B (CHB) patients who fail to respond to rescue therapy for drug resistance. We analyzed the efficacy of ETV-ADV combi...
Autores principales: | Kim, Jeong Han, Ahn, Sung Hyun, Ko, Soon Young, Choe, Won Hyeok, Kim, Kyun-Hwan, Kwon, So Young |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Association for the Study of the Liver
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946405/ https://www.ncbi.nlm.nih.gov/pubmed/27304549 http://dx.doi.org/10.3350/cmh.2015.0053 |
Ejemplares similares
-
Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy
por: Park, Jung Gil, et al.
Publicado: (2015) -
Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response
por: Woo, Hyun Young, et al.
Publicado: (2020) -
Lamivudine plus adefovir combination therapy for lamivudine resistance in hepatitis-B-related hepatocellular carcinoma patients
por: Kim, Jeong Han, et al.
Publicado: (2013) -
Switch to tenofovir-based therapy or to continue adefovir-based therapy in CHB patients with suboptimal response to adefovir-based combination?
por: Song, Byung-Cheol
Publicado: (2016) -
Efficacy of switching from adefovir to tenofovir in chronic hepatitis B patients who exhibit suboptimal responses to adefovir-based combination rescue therapy due to resistance to nucleoside analogues (SATIS study)
por: Lee, Hye Won, et al.
Publicado: (2016)